Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 12/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 11/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30360207 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11CSNK1DMAPK9MAPK10 | |
| Hydrochloric Acid SCHEMBL30365037 | 0.99 | MAPK14 (0.97) | MAPK14MAPK11CSNK1DMAPK9MAPK10 | |
| SCHEMBL1752996 | 0.84 | MAPK14 (1.00) | MAPK14MAPK11CSNK1DADORA2AADORA1 | |
| SCHEMBL1753071 | 0.84 | MAPK14 (1.00) | MAPK14MAPK11CSNK1DADORA2AADORA1 | |
| SCHEMBL16092111 | 0.82 | MAPK14 (0.69) | MAPK14MAPK11CSNK1DMAPK9MAPK10 | |
| SCHEMBL16092113 | 0.80 | MAPK14 (1.00) | MAPK14MAPK11CSNK1DADORA2AADORA1 | |
| SCHEMBL17728200 | 0.80 | MAPK11 (0.66) | MAPK14MAPK11CSNK1D | |
| SCHEMBL6515131 | 0.79 | MAPK14 (0.65) | MAPK14MAPK11CSNK1DMAPK9MAPK10 | |
| SCHEMBL5847752 | 0.79 | MAPK14 (0.65) | MAPK14MAPK11CSNK1DMAPK9MAPK10 | |
| SCHEMBL16061090 | 0.79 | MAPK14 (0.65) | MAPK14MAPK11CSNK1DMAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566016-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2022-01-13 | — | — | US | disclosed |
| US-11149020-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3842424-A1 | MAP KINASE MODULATORS AND USES THEREOF IN THE TRETAMENT OF TAUOPATHIES | The Trustees of Columbia University in the City of New York (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3521284-B1 | PYRAZINE COMPOUNDS AS MAP KINASE MODULATORS AND USES THEREOF | UNIV COLUMBIA (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10428047-B2 | MAP kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3521284-A1 | PYRAZINE COMPOUNDS AS MAP KINASE MODULATORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20170369472-A1 | MAP KINASE MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-28 | — | — | US | disclosed |
| US-9783525-B2 | Map kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783525-B2 | Map kinase modulators and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160151366-A1 | Compositions and Methods for Treating Autism Spectrum Disorders | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-06-02 | — | — | US | disclosed |
| US-20160151366-A1 | Compositions and Methods for Treating Autism Spectrum Disorders | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-06-02 | — | — | US | disclosed |
| US-20160130253-A1 | MAP KINASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2016-05-12 | — | — | US | disclosed |
| US-20160130253-A1 | MAP KINASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2016-05-12 | — | — | US | disclosed |
| WO-2014145485-A2 | MAP KINASE MODULATORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428047-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | MAPK14 40/4885MAPK11 47/4885CSNK1D 617/4885 |
| US-20160130253-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | MAPK14 40/4885MAPK11 47/4885CSNK1D 617/4885 |
| US-20170369472-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | MAPK14 40/4885MAPK11 47/4885CSNK1D 617/4885 |
| US-11566016-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | MAPK14 40/4885MAPK11 47/4885CSNK1D 617/4885 |
| US-11149020-B2 | MAP kinase modulators and uses thereof | MAPK1, MAP3K1, MAP3K2 | MAPK14 40/4885MAPK11 47/4885CSNK1D 617/4885 |
| US-20160151366-A1 | Compositions and Methods for Treating Autism Spectrum Disorders | GRIN2A, GRIN2C, NTRK2 | MAPK14 124/4885MAPK11 66/4885CSNK1D 271/4885 |
| US-20220009905-A1 | MAP KINASE MODULATORS AND USES THEREOF | MAPK1, MAP3K1, MAP3K2 | MAPK14 40/4885MAPK11 47/4885CSNK1D 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.